藥物輸送聯合研究與許可協議（2019-2024）

Drug Delivery Collaboration and Licensing Deals 2019-2024

出版日期: 2024年11月01日 | 出版商:

Current Partnering | 英文 750+ Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

該報告審查了藥物輸送合作和許可協議，以詳細瞭解和分析了公司如何以及為何簽訂藥物輸送協議。

介紹
過去幾年的藥品傳輸合約
最活躍的藥物傳輸合約公司
藥物輸送：依合約類型
藥物傳輸：按治療領域
藥物輸送：依行業分類
藥物輸送協議的條款與條件
- 藥品配送合約總金額
- 藥物輸送合約的預付款
- 藥物輸送合約的里程碑付款
- 藥物輸送特許權使用費率

第3章重大藥品輸送合約

介紹
按價值排名最高的藥物輸送合約

第4章：最活躍的藥品輸送合約公司

介紹
最活躍的藥物傳輸合約公司
最活躍的藥物傳輸合約公司概況

第5章藥品交付合約名錄

介紹
藥品輸送合約目錄

第6章藥品輸送合約：依技術類型

合約目錄
合約目錄 - 藥物輸送合約：按公司（AZ）
合約目錄 - 藥品輸送合約：依合約類型
合約目錄 - 藥物傳輸合約：依治療領域
定義合約類型
關於Biopharma Research Ltd
目前的合作夥伴
目前協議
目前合作夥伴最近報告的標題

簡介目錄

Product Code: CP2102

Drug Delivery Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the drug delivery deals entered into by the world's leading biopharma companies.

Fully revised and updated, the report provides details of drug delivery deals from 2019 to 2024.

The report provides a detailed understanding and analysis of how and why companies enter drug delivery deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

The report includes collaboration, development, research and licensing deals.

This report contains a comprehensive listing of 1202 drug delivery deals announced since 2019 including financial terms where available including links to online deal records of actual drug delivery partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of drug delivery dealmaking.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in drug delivery dealmaking since 2019.

Chapter 3 provides an overview of the leading drug delivery deals since 2019. Deals are listed by headline value.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in drug delivery dealmaking with a brief summary followed by a comprehensive listing of drug delivery deals, as well as contract documents available in the public domain.

Chapter 5 provides a comprehensive and detailed review of drug delivery deals signed and announced since Jan 2019, where a contract document is available in the public domain.

Chapter 6 provides a comprehensive and detailed review of drug delivery partnering deals signed and announced since Jan 2019. The chapter is organized by specific drug delivery technology type in focus.

The report also includes numerous table and figures that illustrate the trends and activities in drug delivery deal making since 2019.

In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Drug Delivery Collaboration and Licensing Deals provides the reader with the following key benefits:

Understand deal trends since 2019
Browse drug delivery collaboration and licensing deals
Benchmark analysis - identify market value of transactions
Financials terms - upfront, milestone, royalties
Directory of deals by company A-Z, deal type and therapy area
Leading deals by value
Most active dealmakers
Identify assets and deal terms for each transaction
Access contract documents - insights into deal structures
Due diligence - assess suitability of your proposed deal terms for partner companies
Save hundreds of hours of research time

Report scope

Drug Delivery Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of drug delivery trends and structure of deals entered into by leading biopharma companies worldwide.

Drug Delivery Collaboration and Licensing Deals includes:

Trends in drug delivery dealmaking in the biopharma industry
Directory of drug delivery deal records covering pharmaceutical and biotechnology
The leading drug delivery deals by value
Most active drug delivery licensing dealmakers
Drug Delivery Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in drug delivery dealmaking

2.1. Introduction
2.2. Drug delivery deals over the years
2.3. Most active drug delivery dealmakers
2.4. Drug delivery deals by deal type
2.5. Drug delivery deals by therapy area
2.6. Drug delivery deals by industry sector
2.7. Deal terms for drug delivery deals
- 2.7.1 Drug delivery deals headline values
- 2.7.2 Drug delivery deal upfront payments
- 2.7.3 Drug delivery deal milestone payments
- 2.7.4 Drug delivery royalty rates